Next Article in Journal
Applicability of Precision Medicine Approaches to Managing Hypertension in Rural Populations
Next Article in Special Issue
Warfarin: The End or the End of One Size Fits All Therapy?
Previous Article in Journal
Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition
Previous Article in Special Issue
P450 Pharmacogenetics in Indigenous North American Populations
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessFeature PaperReview
J. Pers. Med. 2018, 8(2), 15;

Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics

Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children’s Mercy Kansas City, 2401 Gillham Rd, Kanas City, MO 64108, USA
School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA
College of Pharmacy, University of Chicago, IL 60607, USA
Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA
Author to whom correspondence should be addressed.
Received: 6 February 2018 / Revised: 6 April 2018 / Accepted: 10 April 2018 / Published: 17 April 2018
(This article belongs to the Special Issue Cytochrome P450 Variation in Pharmacogenomics)
Full-Text   |   PDF [1344 KB, uploaded 3 May 2018]   |  


The seminal paper on the CYP2D6 Activity Score (AS) was first published ten years ago and, since its introduction in 2008, it has been widely accepted in the field of pharmacogenetics. This scoring system facilitates the translation of highly complex CYP2D6 diplotype data into a patient’s phenotype to guide drug therapy and is at the core of all CYP2D6 gene/drug pair guidelines issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC). The AS, however, only explains a portion of the variability observed among individuals and ethnicities. In this review, we provide an overview of sources in addition to CYP2D6 genotype that contribute to the variability in CYP2D6-mediated drug metabolism and discuss other factors, genetic and non-genetic, that likely contribute to the observed variability in CYP2D6 enzymatic activity. View Full-Text
Keywords: CYP2D6; activity score; dextromethorphan; inter-individual variability CYP2D6; activity score; dextromethorphan; inter-individual variability

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Gaedigk, A.; Dinh, J.C.; Jeong, H.; Prasad, B.; Leeder, J.S. Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics. J. Pers. Med. 2018, 8, 15.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top